Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26792890 | 0.77 | — | — | |
| SCHEMBL7500408 | 0.75 | SHBG (0.34) | — | |
| SCHEMBL26741297 | 0.74 | APLNR (0.32) | DPP4 | |
| SCHEMBL907511 | 0.73 | DPP4 (0.38) | DPP4 | |
| SCHEMBL24323983 | 0.70 | APLNR (0.32) | — | |
| SCHEMBL466188 | 0.70 | DPP4 (0.36) | DPP4 | |
| SCHEMBL5025923 | 0.69 | — | — | |
| SCHEMBL6082609 | 0.69 | — | — | |
| SCHEMBL2427007 | 0.69 | — | — | |
| SCHEMBL636865 | 0.69 | SHBG (0.40) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1660058-A2 | THE USE OF 1-AMINO-ALKYLCYCLOHEXANE COMPOUNDS IN THE TREATMENT OF PAIN HYPERSENSITIVITY | Merz Pharma GmbH & Co. KGaA (DE) | 2006-05-31 | — | — | EP | claimed |
| WO-2005009421-A2 | THE USE OF 1-AMINO-ALKYLCYCLOHEXANE COMPOUNDS IN THE TREATMENT OF PAIN HYPERSENSITIVITY | MERZ PHARMA GMBH & CO. KGAA (DE) | 2005-02-03 | — | — | WO | claimed |
| EP-1318800-A1 | 1-AMINO-ALKYLCYCLOHEXANES AS TRYPANOCIDAL AGENTS | MERZ + CO. GmbH & Co. (DE) | 2003-06-18 | — | — | EP | claimed |
| EP-1303477-A2 | 1-AMINO-ALKYLCYCLOHEXANES AS 5-HT3- AND NEURONAL NICOTINICRECEPTOR ANTAGONISTS | MERZ + CO. GmbH & Co. (DE) | 2003-04-23 | — | — | EP | claimed |
| WO-2002024186-A1 | 1-AMINO-ALKYLCYCLOHEXANES AS TRYPANOCIDAL AGENTS | MERZ PHARMA GMBH & CO. KGAA (DE) | 2002-03-28 | — | — | WO | claimed |
| WO-2001098253-A2 | 1-AMINO-ALKYLCYCLOHEXANES AS 5-HT3 AND NEURONAL NICOTINICRECEPTOR ANTAGONISTS | MERZ PHARMA GMBH & CO. KGAA (DE) | 2001-12-27 | — | — | WO | claimed |
| US-20100076073-A1 | Combination of an NMDA receptor antagonist and a selective serotonin reuptake inhibitor for the treatment of depression and other mood disorders | MERZ PHARMA GMBH & CO. KGAA (DE) | 2010-03-25 | — | — | US | disclosed |
| EP-1684715-A2 | COMPOSITIONS COMPRISING CYCLOHEXYLAMINES AND AMINOADAMANTANES | Merz Pharma GmbH & Co. KGaA (DE) | 2006-08-02 | — | — | EP | disclosed |
| EP-1660058-A2 | THE USE OF 1-AMINO-ALKYLCYCLOHEXANE COMPOUNDS IN THE TREATMENT OF PAIN HYPERSENSITIVITY | Merz Pharma GmbH & Co. KGaA (DE) | 2006-05-31 | — | — | EP | disclosed |
| US-20050203191-A1 | 1-Aminocyclohexane derivatives for the treatment of agitation and other behavioral disorders, especially those associated with alzheimer's disease | FOREST LABORATORIES, INC. (US) | 2005-09-15 | — | — | US | disclosed |
| WO-2005044228-A2 | COMPOSITIONS COMPRISING CYCLOHEXYLAMINES AND AMINOADAMANTANES | MERZ PHARMA GMBH & CO. KGAA (DE) | 2005-05-19 | — | — | WO | disclosed |
| WO-2005009421-A2 | THE USE OF 1-AMINO-ALKYLCYCLOHEXANE COMPOUNDS IN THE TREATMENT OF PAIN HYPERSENSITIVITY | MERZ PHARMA GMBH & CO. KGAA (DE) | 2005-02-03 | — | — | WO | disclosed |
| EP-1318800-A1 | 1-AMINO-ALKYLCYCLOHEXANES AS TRYPANOCIDAL AGENTS | MERZ + CO. GmbH & Co. (DE) | 2003-06-18 | — | — | EP | disclosed |
| EP-1303477-A2 | 1-AMINO-ALKYLCYCLOHEXANES AS 5-HT3- AND NEURONAL NICOTINICRECEPTOR ANTAGONISTS | MERZ + CO. GmbH & Co. (DE) | 2003-04-23 | — | — | EP | disclosed |
| WO-2002024186-A1 | 1-AMINO-ALKYLCYCLOHEXANES AS TRYPANOCIDAL AGENTS | MERZ PHARMA GMBH & CO. KGAA (DE) | 2002-03-28 | — | — | WO | disclosed |
| WO-2001098253-A2 | 1-AMINO-ALKYLCYCLOHEXANES AS 5-HT3 AND NEURONAL NICOTINICRECEPTOR ANTAGONISTS | MERZ PHARMA GMBH & CO. KGAA (DE) | 2001-12-27 | — | — | WO | disclosed |
| EP-1009732-A2 | 1-AMINO-ALKYLCYCLOHEXANE NMDA RECEPTOR ANTAGONISTS | MERZ + CO. GmbH & Co. (DE) | 2000-06-21 | — | — | EP | disclosed |
| WO-1999001416-A2 | 1-AMINO-ALKYLCYCLOHEXANE NMDA RECEPTOR ANTAGONISTS | MERZ + CO. GMBH & CO. (DE) | 1999-01-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050203191-A1 | 1-Aminocyclohexane derivatives for the treatment of agitation and other behavioral disorders, especially those associated with alzheimer's disease | ACHE, PNMT, APH1A | DPP4 2950/4885 |
| US-20100076073-A1 | Combination of an NMDA receptor antagonist and a selective serotonin reuptake inhibitor for the treatment of depression and other mood disorders | GRIN2A, GRIN2B, GRIN3B | DPP4 2064/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.